Funding Agreements in the Biotechnology Industry

54 Contracts & Agreements

Browse by Company

Adhera Therapeutics, Inc. (5 contracts)
AmpliPhi Biosciences Corp (3)
Aptose Biosciences Inc. (1)
Arsanis, Inc. (11)
ARYA Sciences Acquisition Corp II (2)
aTYR PHARMA INC (1)
AZIYO BIOLOGICS, INC. (1)
BioCardia, Inc. (1)
Biohaven Pharmaceutical Holding Co Ltd. (2)
BURZYNSKI RESEARCH INSTITUTE INC (1)
CAPRICOR THERAPEUTICS, INC. (1)
CytoDyn Inc. (1)
Cytokinetics, Incorporated (1)
Dermavant Sciences Ltd (2)
DiaMedica Therapeutics Inc. (1)
HEAT BIOLOGICS, INC. (1)
IDERA PHARMACEUTICALS, INC. (1)
IMMUNOMEDICS INC (1)
Kodiak Sciences Inc. (1)
MATEON THERAPEUTICS INC (1)
NOVAVAX INC (2)
PTC THERAPEUTICS, INC. (2)
Rich Pharmaceuticals, Inc. (2)
RITTER PHARMACEUTICALS INC (1)
SANGAMO THERAPEUTICS, INC (1)
Vaccitech plc (1)
VBI Vaccines Inc (3)
VICAL INC (1)
Xenetic Biosciences, Inc. (2)

Recent Contracts

Funding Agreement by and between the Registrant, Coalition for Epidemic Preparedness Innovations and the University of Oxford, dated as of December 20, 2023 (Vaccitech plc, Filed With SEC on March 20, 2024)
Funding Satisfaction Agreement (Aptose Biosciences Inc., Filed With SEC on January 30, 2024)
Amendment Letter, dated November 8, 2023, by and between Elutia Inc. and SWK Funding LLC (AZIYO BIOLOGICS, INC., Filed With SEC on November 15, 2023)
Bridge Funding Agreement, dated as of July 11, 2023, by and between Aceragen, Inc. and NovaQuest Co-Investment Fund XV, L.P (IDERA PHARMACEUTICALS, INC., Filed With SEC on July 11, 2023)
Amended and Restated Research Funding Agreement, dated May 22, 2023, by and between the Company and Dr. Stanislaw R. Burzynski (BURZYNSKI RESEARCH INSTITUTE INC, Filed With SEC on May 22, 2023)
Research Funding and Option Agreement, dated March 17, 2023, between the Company and the Scripps Research Institute (Xenetic Biosciences, Inc., Filed With SEC on May 11, 2023)
Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited (PTC THERAPEUTICS, INC., Filed With SEC on April 27, 2023)
Amendment to Funding Agreement, by and between Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc., and the Coalition... (VBI Vaccines Inc, Filed With SEC on March 13, 2023)
Amendments to the Funding Agreement, dated as of May 26, 2010, by and between the Registrant and The Wellcome Trust Limited (PTC THERAPEUTICS, INC., Filed With SEC on February 21, 2023)
Master Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated May 26, 2022 (RITTER PHARMACEUTICALS INC, Filed With SEC on June 2, 2022)
Funding Agreement, by and between Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc., and the Coalition for Epidemic... (VBI Vaccines Inc, Filed With SEC on March 7, 2022)
Funding Agreement, dated as of April 12, 2021, by and between Cerevel Therapeutics, Inc. and BC Pinnacle Holdings, LP (ARYA Sciences Acquisition Corp II, Filed With SEC on May 17, 2021)
Funding Agreement, dated as of April 12, 2021, by and between Cerevel Therapeutics, Inc. and NovaQuest Co-Investment Fund XVI, L.P (ARYA Sciences Acquisition Corp II, Filed With SEC on May 17, 2021)
Funding Agreement, by and between Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc., and the Coalition for Epidemic... (VBI Vaccines Inc, Filed With SEC on May 10, 2021)
Amendment Number 1 to the iPDP and Budget of the Outbreak Response Funding Agreement (Step 2), entered into on November 2, 2020, between Novavax, Inc. and the Coalition for... (NOVAVAX INC, Filed With SEC on March 1, 2021)
Funding Agreement by and (Biohaven Pharmaceutical Holding Co Ltd., Filed With SEC on November 9, 2020)
Funding Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Cytokinetics, Incorporated, Filed With SEC on November 6, 2020)
Research Funding and Option Agreement, dated May 15, 2020, between the Company and the Scripps Research Institute (Xenetic Biosciences, Inc., Filed With SEC on August 12, 2020)
Restated Funding Agreement, entered into on May 11, 2020, by and between the Company and the Coalition for Epidemic Preparedness Innovations (NOVAVAX INC, Filed With SEC on August 10, 2020)
Litigation Funding Agreement dated April 9, 2020, between BSLF, L.L.C. and BioCardia, Inc (BioCardia, Inc., Filed With SEC on April 14, 2020)
Litigation Funding Agreement, dated as of December 27, 2019, between LEGALIST FUND II, L.P. and DiaMedica Therapeutics Inc (DiaMedica Therapeutics Inc., Filed With SEC on January 3, 2020)
Funding Agreement, dated as of December 1, 2019, between Kodiak Sciences Inc., Kodiak Sciences GmbH and Baker Bros. Advisors, LP (Kodiak Sciences Inc., Filed With SEC on December 2, 2019)
Funding Agreement, as amended, dated June 2, 2019, by and between Brickell Biotech, Inc. and NovaQuest Co-Investment Fund X, L.P (VICAL INC, Filed With SEC on September 3, 2019)
First Amendment, effective as of October 11, 2018, to the Funding Agreement, dated as of July 10, 2018, by and between Dermavant Sciences GmbH and NovaQuest Co-Investment Fund... (Dermavant Sciences Ltd, Filed With SEC on May 24, 2019)
Funding Agreement, dated as of July 10, 2018, by and between Dermavant Sciences GmbH and NovaQuest Co-Investment Fund VIII, L.P (Dermavant Sciences Ltd, Filed With SEC on May 24, 2019)
Funding Agreement, dated June 18, 2018, by and between Biohaven Pharmaceutical Holding Company Ltd. and RPI Finance Trust (Biohaven Pharmaceutical Holding Co Ltd., Filed With SEC on June 25, 2018)
Funding Agreement, dated as of January 7, 2018, between the Company and RPI Finance Trust (IMMUNOMEDICS INC, Filed With SEC on May 9, 2018)
Funding contract, dated March 23, 2017, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated July 14, 2016, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated July 20, 2015, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated July 20, 2015, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated June 9, 2014, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated April 3, 2014, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated August 6, 2013, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated March 29, 2013, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated December 5, 2012, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated July 2, 2012, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding contract, dated September 20, 2011, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Arsanis, Inc., Filed With SEC on October 20, 2017)
Funding Commitment issued by Heat Biologics, Inc. dated April 6, 2017 (HEAT BIOLOGICS, INC., Filed With SEC on April 7, 2017)
Amended and Restated Investment Agreement dated May 19, 2015 with LG Capital Funding , LLC (Rich Pharmaceuticals, Inc., Filed With SEC on June 11, 2015)